Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia

NCT03094611 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped the study was closed early due to competing trials

Conditions

CD22 Positive
Recurrent Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: Inotuzumab Ozogamicin

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]